Zealand Pharma A/S (CPSE: ZEAL)
Health Care · Biotechnology · DK
Dkr234.80
-1.34% today · -52.9% 1Y
Zealand Pharma A/S (CPSE: ZEAL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.43B and employs 578 people.
Over the last twelve months the share price has lost 52.9%, trading between 233.50 and 556.00.
Tweenvest scores Zealand Pharma A/S across four factors: quality 47/100, value 55/100, growth 100/100. Its strongest factor is growth.
ZEAL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.43B
- Revenue (TTM)
- $709.63M
- P/E
- 6.18
- EPS
- 38.53
- Dividend yield
- —
- Beta (5Y)
- 0.61
- 52-week high
- Dkr556.00
- 52-week low
- Dkr233.50
- Avg volume (3M)
- —
- Shares outstanding
- 68.11M
- Employees
- 578
- Next earnings
- —
About Zealand Pharma A/S
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
- ISIN
- DK0060257814
- Founded
- 1997
- Listed since
- Nov 23, 2010
- Exchange
- OMX Nordic Exchange Copenhagen
- Currency
- DKK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BGI Genomics Co., Ltd.SZSE: 300676 | $2.61B | CN¥45.47 | -0.85% |
| NewAmsterdam Pharma Company N.V.NasdaqGM: NAMS | $2.58B | $21.48 | -0.44% |
| Beam Therapeutics Inc.NasdaqGS: BEAM | $2.57B | $25.38 | -1.25% |
| Sinocelltech Group LimitedSHSE: 688520 | $2.54B | CN¥36.22 | -2.24% |
| Disc Medicine, Inc.NasdaqGM: IRON | $2.38B | $61.20 | -1.39% |
| SELLAS Life Sciences Group, Inc.NasdaqCM: SLS | $2.35B | $11.89 | +2.06% |
| Celldex Therapeutics, Inc.NasdaqCM: CLDX | $2.35B | $29.50 | -1.30% |
| Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX | $2.34B | $3.95 | -9.52% |
Figures last refreshed Oct 11, 2026.